Biotech giant Gilead Sciences, Inc. (GILD) has gained 16.8% in the past three months compared with the industry’s growth of 7.6%. The stock has also outperformed the sector and the S&P 500.The stock’s performance was hit by pipeline setbacks earlier in the year. Nonetheless, this month, Gilead reported better-than-expected second-quarter results and raised its annual earnings guidance. Revenues increased 5% from the year-ago quarter’s level due to high HIV, oncology and liver disease drug sales. Earnings al ...

Gilead Sciences, Inc. (GILD) announced that the FDA has granted accelerated approval to seladelpar for the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA), in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.The candidate was approved under the brand name Livdelzi.PBC is a rare, chronic, autoimmune disease of the bile ducts that currently has no cure.PBC affects approximately 130,000 Americans, primarily ...

Gilead Sciences says it uncovered a dangerous drug-counterfeiting operation in which its HIV medications were tampered with and improperly resold before reaching patients.The scheme, allegedly run out of two New York City pharmacies, identified Peter Khaim, a twice-convicted medical fraudster, as the mastermind, according to court documents unsealed this month. The company described Khaim as one of the most brazen and largest manufacturers and sellers of counterfeit Gilead medications in the country.Gilead ...

On Thursday, Gilead Sciences, Inc. GILD reported second-quarter revenue of $6.95 billion, beating the consensus of $6.72 billion.Sales increased 5% year over year primarily due to higher product sales in HIV, Liver Disease, and Oncology. Product sales excluding Veklury increased 6% year-over-year to $6.7 billion.Adjusted EPS was $2.01, up from $1.34 a year ago, beating the consensus of $1.60, primarily driven by lower operating expenses and higher revenues.Also Read: Gilead’s $42.5K Priced HIV Drug Could Be ...

Gilead Sciences cites strong growth in its HIV and oncology portfolios during Q2 2024.Key PointsRevenue of $7.0 billion, up 6% excluding Veklury.Non-GAAP diluted EPS of $2.01.Management maintained full-year guidance for product sales.Gilead Sciences (GILD -3.23%), the biopharmaceutical giant known for its HIV, liver disease, and oncology treatments, announced its second quarter 2024 earnings on Aug. 8. The company reported revenue of $7.0 billion, reflecting a solid performance, particularly in its core HIV ...

Gilead Sciences, Inc. (GILD) reported better-than-expected results in the second quarter and raised its annual earnings guidance.Adjusted earnings per share (EPS) of $2.01 comfortably beat the Zacks Consensus Estimate of $1.61. In the year-ago quarter, the company reported adjusted earnings of $1.34 per share.The year-over-year increase was driven by higher revenues and lower operating expenses.Total revenues of $6.9 billion beat the Zacks Consensus Estimate of $6.6, primarily due to high HIV, oncology and ...

Gilead Sciences, Inc. (NASDAQ:GILD) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Cindy Perettie - Executive Vice President, Kite Conference Call Participants Evan Seigerman - BMO Capital Markets Terence Flynn - Morgan Stanley Daina Graybosch - Leerink ...

Gilead Sciences (GILD) reported $6.95 billion in revenue for the quarter ended June 2024, representing a year-over-year increase of 5.4%. EPS of $2.01 for the same period compares to $1.34 a year ago.The reported revenue represents a surprise of +4.71% over the Zacks Consensus Estimate of $6.64 billion. With the consensus EPS estimate being $1.61, the EPS surprise was +24.84%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Stre ...

Gilead Sciences (GILD) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.61 per share. This compares to earnings of $1.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 24.84%. A quarter ago, it was expected that this HIV and hepatitis C drugmaker would post a loss of $1.49 per share when it actually produced a loss of $1.32, delivering a surprise of 11.41%.Over the last four quar ...

Q224 Financial Results August 8, 2024 Forward-Looking Statements Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead's ability to achieve its anticipated full ye ...